CDSCO vs FDA vs EU MDR for Biocompatibility Files

Compare the Documentation Checkpoints Before Reusing the File

A genuinely reusable core package can be valuable. That usually includes the current device description, patient-contacting materials, contact duration, manufacturing and sterilization context, available chemistry data, testing reports, and the risk-management bridge behind the biological evaluation.

This comparison focuses on the market-facing checks. For the separate workflow of deciding what to retain, adapt, or reassess in an existing package, see reusing one ISO 10993 evidence file across FDA, EU MDR, and CDSCO routes.

CDSCO: The India Pathway and Dossier Context Matter First

For India submissions, the practical question is often not "What does CDSCO want instead of ISO 10993?" It is "How should the biological evaluation material be organized and justified for the actual MDR 2017 route being used?"

Start with the applicable route under India's Medical Devices Rules, 2017. For example, CDSCO's Class C/D manufacturing checklist requests a Device Master File aligned with Appendix II of the Fourth Schedule and biocompatibility validation data where applicable. That is a route-specific example, not a universal test list or a statement that every device follows the same dossier route.

• Documentation check: record the selected India route, the responsible applicant, the applicable dossier section, and the device-specific evidence supporting that section.
• What often goes wrong: a team drops an FDA or EU-style summary into the file without checking whether the India dossier framing, materials description, and test evidence are aligned to the actual submission plan.
• What can travel: core endpoint logic, test reports, chemistry evidence, and risk reasoning, if they are still device-current and not route-dependent in wording.

For a bounded review of the biological-evidence portion, see CDSCO biological evaluation and documentation support. MedDev Advisory provides independent evidence and documentation consulting, not laboratory testing, applicant representation, or licensing execution.

FDA: Connect the Evidence to the Finished Device

FDA may rely on ISO 10993-1, but it applies that framework in a very explicit, submission-facing way. FDA's biocompatibility resources emphasise that the device is assessed in its final finished form, including sterilization where relevant, and that risk assessment must consider not just materials, but also processing, manufacturing methods, and residuals.

• What reviewers expect: a clear explanation of tissue contact, duration, endpoint selection, omitted endpoints, chemistry rationale, and how all of that applies to the marketed device configuration.
• What often goes wrong: teams present material-level comfort statements without a device-level risk story, or they rely on old test reports without explaining what current manufacturing or sterilization does to the final risk position.
• Documentation check: identify the finished configuration represented by each report, explain any differences from the submitted device, and record the evidence or rationale used to address each relevant endpoint.

A material declaration or old test report is an input, not a complete finished-device assessment. The summary should make its applicability, limitations, and remaining evidence gaps clear.

EU MDR: Cross-Reference the Evidence to Applicable GSPRs

Annex I, Chapter II, Section 10 focuses on chemical, physical, and biological properties, including materials, compatibility with tissues and body fluids, contaminants and residues, and substances or particles released from the device. Annex II section 4 requires the technical documentation to identify the controlled evidence supporting conformity with applicable general safety and performance requirements. Section 6.1(b) addresses biocompatibility information and identification of materials in direct or indirect patient or user contact; where no new testing is undertaken, a rationale is required.

• What reviewers expect: the biological evaluation should be coherent with risk management, design information, chemistry, PMS thinking where relevant, and the broader technical documentation.
• What often goes wrong: the file contains decent evidence, but the links back to the applicable GSPRs are implied rather than explicit.
• Documentation check: cross-reference each applicable GSPR to the controlled report or rationale, including its version and location, rather than relying on a general statement that the device is biocompatible.

These emphases are not exclusive: finished-device relevance and evidence traceability matter across markets. The task is to make both visible within the applicable submission structure.

Where One Cross-Market File Usually Breaks

Reuse can fail when a narrative is carried over without checking the device, evidence scope, and destination requirements. Check these points before adapting an existing file:

• Copied endpoint tables: the table travels, but the explanation for why those endpoints are sufficient is market-specific.
• Waiver rationale that is technically true but badly framed: acceptable science can still be communicated in the wrong regulatory language.
• Chemistry without placement: extractables, residuals, or TRA outputs exist, but the file does not show where they support the biological conclusion.
• Route ambiguity: the team has not fully resolved whether the file is serving India planning, FDA premarket review, EU MDR technical documentation, or all three at once.
• Version drift: test reports and materials history reflect an older device state than the one now being submitted.

A More Workable Multi-Market Strategy

The better approach is to build one defensible evidence core and three market-facing wrappers around it.

• Core evidence layer: device definition, patient-contacting materials, manufacturing and sterilization context, chemistry, testing, literature, and risk-management bridge.
• India layer: confirm the actual MDR 2017 route, applicant context, dossier structure, and where biological evidence needs to sit within that pathway.
• FDA layer: build a concise finished-device argument that explains why the current marketed configuration is adequately assessed.
• EU MDR layer: map the same evidence back to Annex I requirements and technical-documentation cross-references.

The practical output is a short market-specific gap list: the document or evidence affected, why it does not yet fit, the next action, and who owns that action. A formatting change alone cannot resolve missing or inapplicable evidence.